NASDAQ: APGEApogee Therapeutics Inc Stock
$52.20+1.29 (+2.53%)
Updated May 2, 2024
APGE Price
$52.20
Fair Value Price
$2.30
Market Cap
$2.64B
52 Week Low
$14.19
52 Week High
$72.29
P/E
-15.54x
P/B
6.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$83.99M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$75M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
APGE Overview
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APGE ($52.20) is overvalued by 2,173.98% relative to our estimate of its Fair Value price of $2.30 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
APGE ($52.20) is not significantly undervalued (2,173.98%) relative to our estimate of its Fair Value price of $2.30 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
APGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APGE due diligence checks available for Premium users.
Be the first to know about important APGE news, forecast changes, insider trades & much more!
APGE News
Valuation
APGE fair value
Fair Value of APGE stock based on Discounted Cash Flow (DCF)
Price
$52.20
Fair Value
$2.30
Overvalued by
2,173.98%
APGE ($52.20) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APGE ($52.20) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APGE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-15.54x
Industry
7.63x
Market
35.48x
APGE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.96x
Industry
5.99x
APGE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APGE's financial health
Profit margin
Revenue
$0.0
Net Income
-$31.7M
Profit Margin
0%
APGE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$401.4M
Liabilities
$21.5M
Debt to equity
0.06
APGE's short-term assets ($398.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APGE's short-term assets ($398.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.8M
Investing
-$39.7M
Financing
-$213.0k
APGE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APGE vs Biotech Stocks
Apogee Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.